Tetra Offers Pro-Bono Regulatory and Quality Assurance Expertise to Companies Developing COVID-19 Solutions

TETRA BIO-PHARMA VOLUNTEERS TO GUIDE MEDICAL DEVICE/ HEALTH-RELATED MANUFACTURERS

OTTAWA, April 8, 2020 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development has joined the battle to fight the novel COVID-19 virus. The Company will mobilize its expertise in regulatory affairs and quality assurance to support Canadian businesses seeking Health Canada approval for specific products used to mitigate the ongoing COVID-19 pandemic.

This week Tetra Bio-Pharma submitted a Drug Information Number (DIN) application to Health Canada on behalf of a Canadian company ready to produce a hospital, institutional grade hard surface disinfectant. Tetra provided its intellectual know-how on a pro-bono basis. These regulatory services would typically cost companies thousands of dollars using a third-party service provider. Equally important are the efficiencies and time savings realized, which could mean a faster delivery of goods that are in tremendous demand.

"COVID-19 is unprecedented in our lifetime and calls for an unprecedented response from all of us," says Tetra Bio-Pharma CEO and CRO, Dr. Guy Chamberland. Our staff of more than 30 experts in the fields of medical devices and drugs have decades of experience and regulatory knowledge in preparing and filing applications to regulators like Health Canada and FDA. Tetra also enjoys numerous years of experience in Quality Assurance (QA) with a team experienced in international requirements for drugs and medical devices. Helping these entrepreneurs secure approvals and avoid unnecessary delays in doing so may help save lives, which is why we support these efforts at 100 percent. Needless to say, this goes beyond our normal daily routine, our top priorities remain the SERENITY©, PLENITUDE© and HCC-011 projects".

"We are committed to doing whatever we can to help flatten the curve of this life-threating virus." said Tetra's President Sylvain Chrétien. "The Tetra team is used to going above and beyond the call of duty and our QA and regulatory affairs colleagues have the ability to provide the kind of insights that could bring these vital products to the frontline faster. Tetra is pleased to be able to use its internal resources to provide these services without the Company incurring additional expenses.

About Tetra Bio-Pharma

Tetra Bio-Pharma (TSX-V: TBP ) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed and approved, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research and development strategies, including the success of this product or any other product, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

SOURCE Tetra Bio-Pharma

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2020/08/c4356.html